Aviptadil Research

Chanchalani G

How to cite this article: Chanchalani G. Aviptadil in Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage? Indian J Crit Care Med 2025;29(11):895-896.Copyright © 2025; The Author(s).

Udupa AA, Todur P, Chaudhuri S, Gupta N, Bhat VR, Nagendra D et al.

Acute respiratory distress syndrome (ARDS) is a life-threatening condition with a high mortality rate despite advances in supportive care. Aviptadil, a synthetic analogue of vasoactive intestinal peptide (VIP), exhibits anti-inflammatory potential and cytoprotective effects that may improve pulmo...

Chen J, Xu H, Yang L, Chen F, Li K, Xu B et al.

To investigate vasoactive intestinal peptide (VIP) expression and distribution in fetal Sprague-Dawley (SD) rat lung with congenital diaphragmatic hernia (CDH). Assess the impact of VIP analog Aviptadil on CDH-associated lung hypoplasia.CDH was induced in pregnant SD rats by nitrofen gavage on E9...

Esendagli D

Gao C, Lu X

Charles EJ, Shaikh FA, Nemeth ZH

Esendagli D

Al-Mitwalli A, Holden F, Di Giovanni A, Gobbo A, Shah M, Chiriaco G et al.

Intracavernosal injection (ICI), most commonly with alprostadil, is recommended for Phosphodiesterase 5 Inhibitors (PDE5i) nonresponders in erectile dysfunction (ED) treatment; however, its use can cause pain (12%) and priapism (1%).We aimed to evaluate the efficacy of another ICI, Invicorp, and ...

Esendagli D, Sarı N, Akhan S, Arslan S, Doğan Öntaş İA, Yılmaz G et al.

We are still in search of new therapeutic options for COVID-19 to prevent new infections, enable fast recovery, and reduce the long-lasting symptoms or sequelae. This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients.A multic...

Porst H, Lewis R, Virag R, Goldstein I

Although oral phosphodiesterase 5 inhibitors represent a first choice and long-term option for about half of all patients with erectile dysfunction (ED), self-injection therapy with vasoactive drugs remains a viable alternative for all those who are not reacting or cannot tolerate oral drug thera...

Sampley S, Bhasin D, Sekhri K, Singh H, Gupta O

Dealing with life-threatening viral acute respiratory distress syndrome (ARDS) has always been challenging and with the recent COVID pandemic experience, there is still the need of newer therapies to alleviate mortality. Aviptadil, has shown significant beneficial results in covid. We share our e...

Jaimes-Castelán EG, González-Espinosa C, Magos-Guerrero GA, Arrieta-Cruz I, Jiménez-Estrada M, Reyes-Chilpa R et al.

This work aimed to show which treatments showed efficacy against coronavirus disease 2019 (COVID-19); therefore, the results of 37 clinical trials started in 2020 and completed in 2021 are reviewed and discussed here. These were selected from databases, excluding vaccines, computational studies, ...

Nanda C, Mehta C, Mehta Y, Joshi S, Bhan A, Bhan A et al.

Goksu AY, Kocanci FG, Akinci E, Demir-Dora D, Erendor F, Sanlioglu S et al.

A common pathological hallmark of neurodegenerative disorders is neuronal cell death, accompanied by neuroinflammation and oxidative stress. The vasoactive intestinal peptide (VIP) is a pleiotropic peptide that combines neuroprotective and immunomodulatory actions. The gene therapy field shows lo...

Mehta Y, Mehta C, Chandrasekaran A

Acute Respiratory Distress Syndrome (ARDS) is a severe and potentially life-threatening lung condition that often leads to Intensive Care Unit (ICU) admissions. Treating ARDS in the ICU involves providing essential support for proper oxygenation and ventilation, often requiring mechanical ventila...

Vora A, Mehta P, Arora VK, Behera D, Kar A, Katiyar SK et al.

Mahmoudzadeh K, Habibi Z, Yousefi M, Mostafavi M, Mohammadi M

Increasing attention to peptides as prospective therapeutics has created a renaissance in searching for new alternatives to the current peptide synthetic approaches as well as their modification. In this context, it is necessary to develop different approaches for peptide ligation. Using enzymes ...

Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L et al.

There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with...

Auld SC

Boesing M, Abig K, Brändle M, Brutsche M, Burri E, Frye BC et al.

Despite the fast establishment of new therapeutic agents in the management of COVID-19 and large-scale vaccination campaigns since the beginning of the SARS-CoV-2 pandemic in early 2020, severe disease courses still represent a threat, especially to patients with risk factors. This indicates the ...